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Abstract
Background: Prostate cancer incidence, treatment, and survival rates vary throughout
the UK, but little is known about regional differences in quality of survival.
Objective: To investigate variations in patient-reported outcomes betweenUK countries
and English Cancer Alliances.
Design, setting, and participants: A cross-sectional postal survey of prostate cancer
survivors diagnosed 18–42 mo previously.
Outcome measurements and statistical analysis: Urinary, bowel, and sexual problems
and vitality were patient reported using the Expanded Prostate Cancer Index Composite
(EPIC-26) questionnaire. General health was also self-assessed. Regional variations were
identiﬁed using multivariable log-linear regression.
Results and limitations: A total of 35 823 men responded, 60.8% of those invited. Self-
assessed health was signiﬁcantly lower than the UK average in Wales and Scotland.
Respondents reported more urinary incontinence in Scotland, more urinary irritation/
obstruction in Scotland and Northern Ireland (NI), poorer bowel function in Scotland and
NI, worse sexual function in Scotland, and reduced vitality/hormonal function in Scotland,
Wales, andNI. Self-assessed healthwas poorer than the English average in South Yorkshire
and North-East and Cumbria, with more urinary incontinence in North-East and Cumbria
and Peninsula, greater sexual problems inWestMidlands, andpoorer vitality inNorth-East
and Cumbria and West Midlands. Limitations include difﬁculty identifying clinically
signiﬁcant differences and limited information on pretreatment conditions.y These two authors are co-ﬁrst authors.
* Corresponding author. Northern Ireland Cancer Registry, Centre for Public Health, Queen’s Uni-
versity Belfast, Mulhouse Building, Grosvenor Road, Belfast BT12 6DP, Northern Ireland, UK.
Tel. +4428 9097 1623.
onnelly@qub.ac.uk (D.W. Donnelly).E-mail address: david.dhttps://doi.org/10.1016/j.eururo.2019.04.018
0302-2838/© 2019 The Author(s). Published by Elsevier B.V. on behalf of Eur
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncopean Association of Urology. This is an open access article
-nd/4.0/).
Conclusions: Despite adjustment for treatment, and clinical and sociodemographic
factors, quality of survival among prostate cancer survivors varied by area of residence.
Adoption of best practice from areas performing well could support enhanced survival
quality in poorer performing areas, particularly with regard to bowel problems and
vitality, where clinically relevant differences were reported.
Patient summary: We conducted a UK-wide survey of patient's quality of life after
treatment for prostate cancer. Outcomes were found to vary depending upon where
patients live. Different service providers need to ensure that all prostate cancer patients
receive the same follow-up care.
© 2019 The Author(s). Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creati-
vecommons.org/licenses/by-nc-nd/4.0/).
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Prostate cancer is one of the most commonly diagnosed
male cancers in the UK [1], with incidence and survival rates
varying between and within the UK's four constituent
countries (England, Scotland, Wales, and Northern Ireland
[NI]) [1–3]. In particular, higher incidence and better
survival are typically found in more affluent areas [1,4],
possibly reflecting levels of active case finding through
prostate-specific antigen (PSA) testing [5].
Treatment of prostate cancer also varies by NHS Hospital
Trustwithin England [6] and between the four UK countries.
Given that health-related quality of life [7] and urinary,
bowel, sexual, and hormone-related problems [7–9] are
treatment related, these patient-reported outcomes may
also vary countywide. Despite this, little is known about
regional differences in quality of survival. The National
Prostate Cancer Audit reported some variation in outcomes
for radical prostatectomy and radiotherapy patients by care
providers within England and Wales [6]. However, these
results were for localised disease only, while case-mix
adjustment of results was not considered.
With many men living for long periods following their
diagnosis, quality of survival has become increasingly
important. Robust intelligence at regional and national
levels may help identify improvements achievable through
a wider application of practices adopted by the best
performing areas. We have thus investigated variations in
quality of survival between the four UK countries, and
between Cancer Alliances within England.
2. Patients and methods
A cross-sectional postal survey of prostate cancer survivors was
conducted as part of the Life After Prostate Cancer Diagnosis study [10].
2.1. Data collection
Men diagnosed with prostate cancer in the previous 18–42 mo were
identiﬁed from cancer registries in England, Wales, and NI, and from
cancer registry-veriﬁed hospital activity data in Scotland. All health
boards/trusts in Scotland, Wales, and NI and 111 out of 136 English NHS
trusts participated. Overall, 82% of eligible prostate cancer survivors
were posted a questionnaire between October 2015 and November
2016. Two reminders were sent and a Freephone helpline was available.
Menwere requested to return completed surveys to an external provider
(Picker Institute Europe). Stage at diagnosis, area-based quintile of
socioeconomic deprivation (derived from the multiple deprivationmeasure for each nation [11–14]), and Cancer Alliance/Vanguard (CA)
[15] of residence in England were added from cancer registration data.
2.2. Survey
The survey (Supplementary material) included questions on age,
employment status, ethnicity, long-term conditions, height, and weight
(used to calculate body mass index [BMI]), method of presentation, and
treatment type. Method of presentationwas categorised as PSA test only
(available tomen aged 50+ yr on request after they aremade aware of its
potential implications [16]), symptoms only (eg, urinating frequently,
blood in urine, back pain, and joint pain), PSAwith symptoms, and other.
Treatment type(s) included surgery, external-beam radiotherapy (EBRT),
androgen deprivation therapy (ADT), brachytherapy, systemic therapy
(chemotherapy, abiraterone, and enzalutamide), and other treatment.
Absence of treatment alongwith reported active surveillance orwatchful
waiting was categorised as receiving monitoring only.
Health-related quality of life was evaluated using the EQ-5D-5L [17],
with responses coded as “no problems” and “with problems”. The EuroQol
Visual Analogue Scale (EQ-VAS) [17] was used as a self-assessed health
rating on a 0–100 scale, where higher scores represent better health.
Urinary, bowel, sexual, and vitality/hormonal functions were deter-
mined using the 26-item Expanded Prostate Cancer Index Composite
(EPIC-26) questionnaire [18]. Reported prevalence of speciﬁc problems
was based upon the proportion of men reporting moderate/big problems
(or equivalents such as poor/very poor) to individual questions. Summary
scores for EPIC-26 domains were calculated by averaging standardised
scores assigned to each question's responses in that domain. The possible
range of scores is 0–100, with 100 corresponding to no problems.
2.3. Statistical analysis
Item completeness varied by region; thus, to reduce bias resulting from
only including cases with complete data [19], multiple imputation with
chained equations [20] using all sociodemographic and clinical
characteristics, and all EQ-5D-5L, EQ-VAS, and EPIC-26 questions and
scores were utilised. Ten separate imputations were completed, with
results combined using Rubin's rules [21].
The EPIC-26 and EQ-VAS scores were modelled using log-linear
regression. Independent variables included CA/country, stage at
diagnosis, method of presentation, treatment type, age, socioeconomic
deprivation quintile, employment status, ethnicity, history of mental
health problems, BMI, and number of physical and neurological
comorbidities. The models were used to predict a case-mix–adjusted
score for each CA/country by applying the UK distribution for each
independent variable to the model. Robust standard errors were used to
calculate conﬁdence intervals for the adjusted mean scores and to
determine signiﬁcant differences from the UK and English averages,
which were derived by combining the results for the smaller geographic
areas. Analysis was conducted using Stata version 14.0 (StataCorp,
College Station, TX, USA).
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3. Results
3.1. Response rates and data completeness
A total of 35 823 prostate cancer survivors diagnosed in the
previous 18–42 mo responded to the survey—a response
rate of 60.8%, which ranged by country from 57.6% in NI to
64.4% inWales. Within England, response rates were lowest
in London CAs (47.7–48.6%) and highest in Thames Valley
(65.0%; Table 1). Response rates were higher for men aged
55–85 yr from white ethnic groups and for those living in
more affluent areas (Supplementary Table 1).
Completeness of data items ranged from 81.7% for the
urinary irritation/obstruction score to just under 100% for
age. Completeness varied by CA/country, with the greatest
variation for stage at diagnosis (Supplementary Table 2).
Data imputation had minimal impact on mean EQ-VAS and
EPIC-26 scores (Supplementary Table 3).
3.2. Respondent and clinical characteristics
After imputation, mean age was 71.6 yr, ranging from 70.1
(NI) to 73.0 yr (Peninsula). Further respondent character-
istics are presented in Table 1.
[2_TD$DIFF]One-third (33.9%) of respondents[3_TD$DIFF] were PSA-detected;
however, this varied by country from 22.9% in Scotland to
37.0% in NI. Within England, North-West and South-West
London (42.3%) and North-Central and North-East London
(41.4%) had higher proportions of PSA-detected patients
(Table 2 and Supplementary Fig. 1).
Almost two-thirds (64.0%) of respondents were diag-
nosed at stage I/II. East of England (68.9%), East Midlands
(68.8%), and Wales (68.8%) had the highest proportion of
stage I/II prostate cancers, while Scotland had the greatest
proportion of stage IV disease (21.1%; Table 2 and
Supplementary Fig. 1).
Three in 10 respondents (30.0%) reported having surgery.
By country, this proportion was lowest in NI (15.6%), whilst
there was considerable variation in surgery use within
England (24.9% in East Midlands, 42.1% in Kent and
Medway). Use of EBRT was highest in NI (49.2%) and lowest
in Kent andMedway (25.8%). Use of ADTwas highest in East
Midlands (48.0%) and lowest in Kent and Medway (31.6%).
Proportions of “monitoring only” ranged from 12.4% in
Scotland to 20.7% in Kent and Medway (Table 2 and
Supplementary Fig. 2).
3.3. Unadjusted question responses
Among respondents, 62.5% reported problems in at least
one of mobility, self-care, usual activities, pain/discomfort,
or anxiety/depression, with this proportion ranging from56.7% in Surrey and Sussex to 66.7% in[1_TD$DIFF] North-East and
Cumbria. Reporting of moderate/big urinary problems
ranged from 10.9% (Somerset, Wiltshire, Avon and Glou-
cestershire, and Surrey and Sussex) to 18.4% (North-East and
Cumbria), while moderate/big bowel problems ranged from
6.2% (Kent and Medway) to 12.7% (NI). Very poor/poor
ability to perform sexually was reported by 71.0% of South-
East London respondents, increasing to 84.6% in Scotland.
Moderate/big problems with lack of energy were reported
by 18.4% of Kent andMedway respondents, rising to 31.6% in
NI (Supplementary Table 5).
3.4. Case-mix–adjusted summary scores
3.4.1. By country
Mean UK wide scores were 76.1 for self-assessed health,
81.1 for urinary incontinence, 84.1 for urinary irritation/
obstruction, 87.5 for bowel function, 22.0 for sexual
function, and 78.4 for vitality/hormonal function
(100 = no problems).
Compared with these averages, respondents reported
significantly poorer self-assessed health in Wales (74.3,
p < 0.001) and Scotland (75.3, p = 0.037), more urinary
incontinence in Scotland (78.3, p < 0.001), more urinary
irritation/obstruction in Scotland (82.9, p = 0.005) and NI
(82.4, p = 0.002), poorer bowel function in Scotland (86.2,
p = 0.002) and NI (84.8, p < 0.001), worse sexual function in
Scotland (19.9, p < 0.001), and reduced vitality/hormonal
function in Wales (76.6, p < 0.001), Scotland (76.8,
p < 0.001), and NI (75.2, p < 0.001; Table 3).
3.4.2. Within England
Within England, mean scores were 76.3 for self-assessed
health, 81.3 for urinary incontinence, 84.3 for urinary
irritation/obstruction, 87.7 for bowel function, 22.2 for
sexual function, and 78.7 for vitality/hormonal function.
Comparedwith the English average, poorer self-assessed
health was reported in South Yorkshire (75.2, p = 0.015) and
in [1_TD$DIFF] North-East and Cumbria (74.8, p = 0.003). However,
better than average health was reported in Kent and
Medway (77.3, p = 0.021) and South-East London (77.6,
p = 0.037). Respondents from[1_TD$DIFF]North-East and Cumbria (79.4,
p = 0.006) and[1_TD$DIFF] Peninsula (79.8, p = 0.014) reported more
urinary incontinence than in England, while below average
levels of urinary incontinence were reported in Surrey and
Sussex (83.1, p < 0.001). Survivors from South-East London
(85.5, p = 0.048) reported better urinary irritation/obstruc-
tion than the English average, while those from West
Yorkshire (89.5, p < 0.001) and Kent and Medway (88.6,
p = 0.035) reported fewer bowel problems. Poorer than
average sexual function was reported in the West Midlands
(20.8, p < 0.001), while better functioning was reported in
Surrey and Sussex (25.2, p < 0.001), South-East London
(24.3, p = 0.017), and Kent and Medway (23.6, p = 0.018).
Respondents from[1_TD$DIFF] North-East and Cumbria (77.3, p = 0.020)
and West Midlands (77.7, p = 0.004) reported poorer
vitality/hormonal function, while this was better than
average in West Yorkshire (79.8, p = 0.019) and Kent and
Medway (79.8, p = 0.009; Fig.1 and Supplementary Table 6).
[4_TD$DIFF]
nse rates and respondent characteristics at the time of survey by area of residence
e—country
nces/
and)
Number of respondents Response rate (%) Mean age Proportion of prostate cancer survivors
Afﬂuenta Depriveda Married Employed Retired Non-white Overweight Obese With previous
history of mental
health problems
35 823 60.8 71.6 26.9 10.4 80.3 19.8 77.3 3.0 47.8 21.0 17.2
30 463 60.5 71.7 26.9 10.0 80.3 19.8 77.5 3.4 48.1 20.6 17.1
Cumbria 1114 61.5 72.0 24.7 19.2 80.5 15.0 81.0 0.9 48.7 23.1 18.0
South 1203 61.2 71.4 28.2 10.4 79.6 18.0 79.2 0.8 49.0 20.3 16.2
1494 61.3 71.2 29.6 11.8 80.1 18.3 78.9 3.2 46.1 22.6 16.5
and Vale 902 63.0 71.0 28.8 9.6 80.9 17.8 80.2 0.5 47.6 22.7 19.7
erseyside 1255 59.1 71.5 32.6 14.9 78.1 20.0 77.0 0.8 47.7 19.1 18.4
ster 1257 55.8 71.7 26.2 17.9 76.2 18.0 78.7 3.8 47.2 20.7 18.1
, Bassetlaw,
and
1302 64.5 71.9 22.5 16.7 80.1 16.3 81.0 2.1 47.6 21.3 17.0
3196 60.8 71.9 22.5 11.4 81.8 19.7 77.7 2.4 49.7 22.4 17.3
2655 62.7 71.6 27.2 7.7 81.5 18.4 78.6 2.0 48.5 23.0 16.5
4322 62.2 72.0 24.6 4.7 82.2 19.9 78.1 1.7 47.6 20.7 16.3
hire, Avon
re
1616 64.5 72.1 30.6 4.7 81.5 19.0 78.9 0.8 47.5 19.2 16.4
1561 65.0 71.5 53.9 2.0 83.6 25.7 71.9 3.2 47.1 17.7 15.1
South- 1138 48.4 70.8 22.0 14.3 73.3 27.4 68.1 20.2 48.5 14.8 19.9
nd North- 971 48.6 71.2 9.1 36.1 71.7 21.7 74.2 20.6 44.4 22.7 16.9
on 702 47.7 70.4 20.3 20.4 72.2 24.1 70.0 18.1 46.8 19.4 20.2
1184 63.5 73.0 8.9 5.3 82.1 17.6 80.6 0.3 47.1 20.9 17.2
1874 64.0 72.6 29.0 4.0 81.2 17.0 81.0 0.7 49.2 18.6 17.0
ex 1352 64.8 71.7 43.8 3.9 81.6 21.8 75.8 2.0 49.6 17.9 16.5
ay 1365 60.4 70.6 20.5 6.7 81.1 24.0 73.5 1.0 50.2 20.8 16.7
2522 64.4 71.5 25.5 12.7 81.0 19.0 77.8 0.7 46.9 24.9 17.7
1819 62.8 71.0 27.4 12.7 78.9 18.2 76.8 0.3 47.3 23.4 19.5
1019 57.6 70.1 28.6 11.0 80.5 23.5 70.6 0.3 44.6 20.8 16.7
most affluent and deprived areas of that country.
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Area of residenc
and Cancer Allia
Vanguards (Engl
UK
England
North-East and
Lancashire and
Cumbria
West Yorkshire
Humber, Coast
Cheshire and M
Greater Manche
South Yorkshire
North Derbyshire
Hardwick
West Midlands
East Midlands
East of England
Somerset, Wilts
and Gloucestershi
Thames Valley
North-West and
West London
North-Central a
East London
South-East Lond
Peninsula
Wessex
Surrey and Suss
Kent and Medw
Wales
Scotland
Northern Ireland
a Resident in the
portion of prostate cancer survivorsa with selected clinical characteristics by area of residenceb
nce—country
lliances/
ngland)c
Number of respondents Proportion of prostate cancer survi rsd
Presented via
PSA test only
Presented with
symptoms only
Diagnosed at stage I/II Diagnosed at
stage IV
Tre ted
with rgery
Treated
with EBRT
Treated
with ADT
Received
monitoring only
35 823 33.9 52.8 64.0 12.7 3 0 38.9 43.0 16.8
30 463 34.3 52.3 64.4 12.2 3 8 38.5 42.9 16.9
nd Cumbria 1114 24.9 60.6 64.5 16.1 2 4 35.8 42.2 18.9
nd South 1203 31.8 55.0 60.1 14.8 3 1 41.9 46.0 13.8
ire 1494 28.9 58.5 53.5 14.4 3 7 35.3 39.4 18.7
st and Vale 902 30.1 57.2 61.9 11.6 3 2 42.9 47.0 16.4
Merseyside 1255 34.0 52.0 62.7 10.2 2 9 40.5 42.4 18.6
chester 1257 34.3 53.1 67.5 12.1 2 9 40.5 42.3 14.8
ire, Bassetlaw,
ire and
1302 27.2 57.9 62.6 12.4 2 7 40.0 38.4 18.6
ds 3196 35.6 50.6 64.2 12.7 3 6 41.0 45.6 16.5
s 2655 33.0 53.3 68.8 11.8 2 9 40.5 48.0 18.0
nd 4322 34.6 52.3 68.9 10.9 2 4 39.9 45.6 17.3
iltshire, Avon
rshire
1616 34.1 53.4 58.5 13.3 3 5 38.2 44.3 14.9
ey 1561 37.3 49.6 64.8 12.6 3 5 34.4 41.0 15.5
and South- 1138 42.3 42.1 67.2 11.4 3 0 39.0 37.8 16.9
al and North- 971 41.4 44.5 66.4 11.1 3 5 35.8 36.2 13.6
ondon 702 37.1 48.4 66.5 9.5 3 8 29.8 32.2 18.8
1184 34.0 54.4 60.8 13.0 3 6 41.2 44.1 15.5
1874 34.5 52.1 65.4 11.4 2 2 40.6 46.4 15.6
ussex 1352 40.0 48.6 61.7 14.9 2 8 37.3 42.6 17.0
dway 1365 37.4 48.7 65.1 9.6 4 1 25.8 31.6 20.7
2522 35.1 51.3 68.8 11.4 2 0 42.8 42.4 19.3
1819 22.9 64.5 52.6 21.1 2 6 35.5 45.8 12.4
nd 1019 37.0 52.0 63.2 13.4 1 6 49.2 42.7 17.3
n deprivation therapy; EBRT = external beam radiotherapy; PSA = prostate-speciﬁc antigen.
mo after diagnosis.
rsions of these data are available in Supplementary Figs. 1 and 2, while confidence intervals for each proportion are available in Supplementa Table 4.
ee Table 1 for number of respondents by area).
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Table 3 – Case-mix–adjusted predicted mean self-assessed health (EQ-VAS) and urinary, bowel, sexual, and vitality/hormonal function (EPIC-
26) for prostate cancer survivorsa by country of residenceb
Country of
residencec
Mean self-assessed
health rating
(EQ-VAS; 95% CI)
Mean functional outcome score (EPIC-26; 95% CI)
Urinary
incontinence
Urinary
irritation/obstruction
Bowel
function
Sexual
function
Vitality/hormonal
function
UK 76.1
(76.0–76.3)
81.1
(80.9–81.3)
84.1
(83.9–84.3)
87.5
(87.4–87.7)
22.0
(21.8–22.3)
78.4
(78.2–78.5)
England 76.3
(76.2–76.5)
81.3
(81.1–81.6)
84.3
(84.1–84.5)
87.7
(87.6–87.9)
22.2
(22.0–22.5)
78.7
(78.5–78.9)"
Wales 74.3
(73.7–75.0)##
81.2
(80.3–82.0)
83.7
(83.1–84.4)
86.9
(86.3–87.6)
21.7
(20.9–22.5)
76.6
(75.9–77.3)##
Scotland 75.3
(74.6–76.1)#
78.3
(77.2–79.3)##
82.9
(82.1–83.7)#
86.2
(85.4–87.0)#
19.9
(18.9–20.9)##
76.8
(76.0–77.7)##
Northern Ireland 75.6
(74.7–76.6)
80.0
(78.8–81.3)
82.4
(81.4–83.5)#
84.8
(83.6–85.9)##
21.4
(20.3–22.6)
75.2
(74.0–76.3)##
CI = conﬁdence interval; EPIC-26 = Expanded Prostate Cancer Index Composite; EQ-VAS = EuroQol Visual Analogue Scale; "" = higher than UK average
(p < 0.001); " = higher than UK average (p < 0.05); # = lower than UK average (p < 0.05); ## = lower than UK average (p < 0.001).
a Alive 18–42 mo after diagnosis.
b This area-based comparison was conducted using log-linear regression, with results presented as adjusted predicted mean scores. Adjustments were made for
age, socioeconomic deprivation, employment status, marital status, ethnicity, comorbidities, history of mental health problems, body mass index, method of
presentation, stage at diagnosis, and treatment types received. These scores differ from values determined directly from raw data. Higher mean scores represent
better health or fewer difficulties in that domain.
c n = 35 823 (see Table 1 for number of respondents by area).
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Including Wales, Scotland, and NI, along with the English
CAs highlights similar regional variations. In general, men
fromWales, Scotland, and NI report similar outcomes to, or
worse outcomes than, those from CAs with below UK
average outcome scores (Fig. 2 and Supplementary Fig. 3).
4. Discussion
We report the largest, and to our knowledge first, evaluation
of regional variations in prostate cancer patient-reported
outcomes across the UK. Prostate cancer survivors living in
England reported better quality of survival than those from
Wales, Scotland, or NI. Within England, poorer than average
self-assessed health was reported in South Yorkshire and
North-East and Cumbria, while those from North-East and
Cumbria, Peninsula, and West Midlands reported greater
than average difficulties in one or more functional out-
comes. Given that regional variations were independent of
clinical case mix, treatment type, and sociodemographic
characteristics, these inequalities require explanation.
4.1. Service implications
CAs were introduced in England in 2016 [15], with a
principal objective to reduce inequalities in cancer out-
comes. The regional inequalities identified in this study
reinforce the pressing importance for this remit to address
not only survival, but also quality of that survival.
A contributory cause of regional outcome variation may
relate to regional differences in care provision. Detailed
comparison of care pathways and packages of support,
including availability and use of specific therapeuticmodalities and support services, such as access to specialist
nurses, could identify factors linked to enhanced quality of
survival.
Regional differences may also relate to variation in
general population health, as the morbidities reported are
common among older men [22]. Overall and healthy life
expectancy among men aged 65 yr are lower in Scotland,
Wales, and NI than in England [23,24], with the North of
England also having lower overall and healthy life
expectancy compared with the South (with some excep-
tions such as Northumberland) [25]. Additionally, specific
conditions (eg, cardiovascular disease) are more prevalent
in the [5_TD$DIFF]North than in the South of England [26], and in
Scotland and NI than in England [27], and vary by area-
based socioeconomic status [28]. While these issues have
broader service and public health implications, prostate
cancer patients reporting functional problems as a result of
conditions other than prostate cancer could still benefit
from follow-up care.
4.2. Strengths and weaknesses
This study was populationwide; thus, participationwas not
influenced by recruitment bias. However, 39.2% of patients
did not respond to the survey, with regional variation in
response rates and data completeness. In addition, a
different participant identification process was utilised in
Scotland, and not all the English NHS trusts managing
prostate cancer participated. Cumulatively, this may have
resulted in variation in outcome reporting as nonrespon-
ders may have different quality of life experiences than
responders. However, given a response rate of over 60%, a
sample size of approximately 35 800, and the utilisation of
standardised/validated measures [29], this study has
[(Fig._1)TD$FIG]
Fig. 1 – Case-mix–adjusted predicted mean self-assessed health (EQ-VAS) and urinary, bowel, sexual, and vitality/hormonal function (EPIC-26) for
prostate cancer survivors aby area of residence: England only, with comparisons to English average. n = 35 823 (see Table 1 for the number of
respondents by area). This area-based comparison was conducted using log-linear regression, with results presented as adjusted predicted mean
scores. Adjustments were made for age, socioeconomic deprivation, employment status, marital status, ethnicity, comorbidities, history of mental
health problems, body mass index, method of presentation, stage at diagnosis, and treatment types received. These scores differ from values
determined directly from raw data. Higher mean scores represent better health or fewer difficulties in that domain. See Supplementary Fig. 4 for a
map of the areas shown in this figure.
C&M = Cheshire and Merseyside; EE = East of England; EM = East Midlands; EPIC-26 = Expanded Prostate Cancer Index Composite; EQ-VAS = EuroQol
Visual Analogue Scale; GM = Greater Manchester; HC&V = Humber, Coast and Vale; K&M = Kent and Medway; L-NC&NE = North-Central and North-East
London; L-NW&SW = North-West and South-West London; L-SE = South-East London; L&SC = Lancashire and South Cumbria; NE&C = North-East and
Cumbria; NI = Northern Ireland; P = Peninsula; S = Scotland; S&S = Surrey and Sussex; SWAG = Somerset, Wiltshire, Avon and Gloucestershire; SY = South
Yorkshire, Bassetlaw, North Derbyshire and Hardwick; TV = Thames Valley; W =Wales; WE =Wessex; WM =West Midlands; WY =West Yorkshire. a Alive
18–42 mo after diagnosis.
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Fig. 2 – Case-mix–adjusted predicted mean self-assessed health (EQ-VAS) and urinary, bowel, sexual and vitality/hormonal function (EPIC-26) for
prostate cancer survivors aby area of residence: UK wide. n = 35 823 (see Table 1 for the number of respondents by area). This area-based comparison
was conducted using log-linear regression, with results presented as adjusted predicted mean scores. Adjustments were made for age, socioeconomic
deprivation, employment status, marital status, ethnicity, comorbidities, history of mental health problems, body mass index, method of presentation,
stage at diagnosis, and treatment types received. These scores differ from values determined directly from raw data. Higher mean scores represent
better health or fewer difficulties in that domain. Funnel plots of these data are available in Supplementary Fig. 3.
EPIC-26 = Expanded Prostate Cancer Index Composite; EQ-VAS = EuroQol Visual Analogue Scale. a Alive 18–42 mo after diagnosis. The figure contains OS
data (GB) and LPS Intellectual Property (NI) Crown copyright and database right 2018.
E U RO P E AN U RO LOGY 76 ( 2 019 ) 2 2 8 – 2 37 235sufficient statistical power to allow meaningful interpreta-
tion and intercountry benchmarking.
The case-mix adjustment applied indicates that differ-
ences are unlikely to be related to treatment type,
comorbidity, or socioeconomic status. However, this should
only be interpreted in a broad sense, as adjustments were
based on self-reported treatment with no adjustment
possible for treatment intensity (eg, frequency, radiation
fraction, and ADT type) or when patients finished treat-
ment. The latter may be of particular relevance, as while the
18–42 mo time frame was chosen because it represents the
period when initial treatment is complete and quality of life
has begun to stabilise [9,10], awide range of possible patient
pathways and timelines exists. In addition to the above,information on quality of life before diagnosis or equivalent
baseline population datawas not available. Adjustments for
background morbidity levels were thus limited to account-
ing for age, number of comorbidities, and BMI, which
reduces the ability to establish causal links. Finally, the use
of area-based socioeconomic deprivation measures and
employment status at a single time point may not fully
reflect individual-level socioeconomic status.
Whilst statistically significant differences were identi-
fied, there is no consensus as to what magnitude of
difference is clinically meaningful for the EQ-VAS and EPIC-
26 scores when applied across populations. For individual-
level comparisons, the work of Skolarus et al. [30] for EPIC-
26 and Pickard et al. [31] for EQ-VAS suggests that only
EU RO P E AN U RO L OGY 76 ( 2 019 ) 2 2 8 – 2 37236differences between the worst and best performing areas
for bowel and vitality/hormonal function may qualify as
being clinically relevant. In addition, it is important to note
that conclusions about variations at a regional level may not
necessarily reflect the experience of every patient.
4.3. Importance of patient-reported outcomes
There is a need to ensure that patient-reported outcomes
are central and core components of cancer outcomes
research, in order to increase the probability that conclu-
sions are appropriately “patient centred”. There are few
examples of their use in national surveys that are
comprehensive and adequately powered enough to provide
robust data on regional variations. This study has tackled
this issue in a common and complex cancer, and has
demonstrated that this is feasible and necessary, with the
generation of useful intelligence regarding variations
between and within countries. Identification of such
variations can lead to enhanced care provision though
identification of differences in patient pathways in the best
and worst performing areas.
5. Conclusions
Quality of survival among prostate cancer survivors varies
across the UK, with poorer outcomes reported by men from
Scotland,Wales, andNI than bymen from England[6_TD$DIFF]. [7_TD$DIFF]Regional
variation was also demonstrated within England. These
findings highlight the need for further investigation to
identify components of care pathways that predispose to
good or poor outcomes, particularly with regard to bowel
problems and vitality, where clinically relevant differences
were reported. Action is required to ensure that outcomes
are monitored and, where possible, improved so that the
increasing number of men living with and beyond a
diagnosis of prostate cancer [8_TD$DIFF]are offered the best chance
of achieving optimal quality of survival.
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